Adjuvant therapies for cutaneous melanoma have been well studied, and to our knowledge only high-dose interferon alfa-2b shows reproducible benefit.1 Efforts to improve the toxic effects profile of high-dose regimens have included the use of lower doses. We report a case of delayed wound healing secondary to treatment with low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury AF, El Sayed F, Bazex J. Delayed Wound Healing Following Treatment With Low-Dose Interferon Alfa-2b for Cutaneous Melanoma. Arch Dermatol. 2007;143(10):1331-1344. doi:10.1001/archderm.143.10.1339